Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy

Human Pathology

Volumn 29, Issue 10, 1998, Pages 1050-1055

  Trieb, Klemens ^b   Lechleitner, Teresa ^b   Lang, Susanna ^b   Windhager, Reinhard ^b   Kotz, Rainer ^b   Dirnhofer, Stephan ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b NONE

Author keywords

Chemotherapy; Heat shock protein; Osteosarcoma; Predictive marker

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 73; IFOSFAMIDE; METHOTREXATE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OSTEOSARCOMA; PREDICTION; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION; TUMOR IMMUNITY; TUMOR VOLUME;

EID: 0031692853     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90412-9     Document Type: Article

References (39)

1. Bradley G, Juranka PF, Ling V: Mechanisms of multidrug resistance. Biochem Biophys Acta 948:87-128, 1988
2. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427, 1993
3. Link MP, Goorin AM, Horowitz M, et al: Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: Updated results of the Multi-Institutional Osteosarcoma study. Clin Orthop 270:8-14, 1991
4. Winkler K, Beron G, Kotz R, et al: Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study. J Clin Oncol 2:617-624, 1984
5. Winkler K, Bielack S, Delling G, et al: Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (COSS-86). Cancer 66:1703-1710, 1990
6. Bacci G, Springfield D, Capanna R, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremity. Clin Orthop 224:268-276, 1987
7. Rosen G, Caparros B, Groshen S: Primary osteogenic sarcoma of the femur: A model for the use of preoperative chemotherapy in high risk malignant tumors. Cancer Invest 2:181-192, 1984
8. Bacci G, Picci P, Pignatti G, et al: Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities. Clin Orthop 87-98, 1991
9. Campanacci M, Bacci G, Bertoni F, et al: The treatment of osteosarcoma of the extremities: Twenty year's experience at the Instituto Ortopedico Rizzoli. Cancer 48:1569-1581, 1981
10. Eibler F, Giuliano A, Eckhardt J, et al: Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. J Clin Oncol 5:21-26, 1987
11. Petrilli AS, Gentil FC, Epelman S, et al: Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 68:733-737, 1991
12. Scranton PE, DeCicco FA, Totten RS, et al: Prognostic factors in osteosarcoma: A review of 20 years experience at the University of Pittsburgh Health Center Hospitals. Cancer 36:2179-2191, 1975
13. Davies AM, Bell RS, Goodwin PJ: Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 12:423-431, 1994
14. Bentzen SM, Poulsen HS, Kaae S, et al: Prognostic factors in osteosarcomas: A regression analysis. Cancer 62:194-202, 1988
15. Geidel S, Garn M, Gravighoff L, et al: Cardiomopathy after osteosarcoma treatment: A contribution to the cardiotoxicity of adriamycin. Klin Pediatr 203:257-261, 1991
16. Bieling B, Rehan N, Winkler P, et al: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14:848-858, 1996
17. Lindquist S: The heat-shock response. Annu Rev Biochem 55:1151-1191, 1986
18. Welch W: Mammilian stress response: Cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev 72:1063-1081, 1992
19. Kaufmann S: Heat shock proteins and the immune response. Immunol Today 11:129-133, 1990
20. Trieb K, Sztankay A, Hermann M, et al: Do heat shock proteins play a role in Graves' disease? Heat shock protein specific T cells from Graves' disease thyroids do not recognize thyroid epithelial cells. J Clin Endocrinol Metab 77:528-535, 1993
21. de Nagel D, Pierce S: A case for chaperones in antigen processing. Immunol Today 13:86-91, 1992
22. Lamb J, Bal V, Mendez-Samperio P: Stress proteins may provide a link between the immune response to infection and autoimmunity. Int Immunol 1:191-195, 1989
23. Udono H, Srivastava P: Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 178:1391-1396, 1991
24. Suto R, Srivastava P: A mechanism for specific immunogenicity of heat shock protein-chaperoned peptides. Science 269:1585-1589, 1995
25. Wei Y, Zhao X, Kariya Y, et al: Induction of autologous tumor killing by heat tratment of fresh human tumor cells: involvement of gd T cells and heat shock protein 70. Cancer Res 56:1104-1110, 1996
26. Richards EH, Hickey E, Weber L, et al: Effect of overexpression of the small heat shock protein hsp27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 56:2446-2451, 1996
27. - large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood 86:1374-1382, 1985
28. Multhoff G, Botzler C, Jennen L, et al: Heat shock protein 72 on tumor cells. J Immunol 158:4341-4350, 1997
29. Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculosceletal sarcoma. Clin Orthop 153:106-120, 1980
30. Salzer-Kuntschik M, Brand G, Delling G: Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologe 4:135-141, 1983
31. Bankfalvi A, Navabi H, Bier P, et al: Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol 174:223-229, 1994
32. Dahlin DC, Unni KK: Osteosarcoma of bone and its important recognizable varieties. AmJ Surg Pathol 1:61-72, 1977
33. Baldini N, Scotlandi K, Barbanti-Bròdano G, et al: Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N EnglJ Med 333:1380-1385, 1995
34. Onda M, Matsuda S, Higaki S, et al: Erb-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77:71-78, 1996
35. Uozaki H, Horiuchi H, Ishida T, et al: Overexpression of metallothioneins, gluthatione-S-transferase, heat shock protein 72 and lung-related protein in osteosarcoma. Cancer 79:2336-2344, 1997
36. Trieb K, Windhager R, Lang S, et al: Human osteosarcoma infiltrating lymphocytes recognize the heat shock protein 72. Trans Orthop Res Soc 22:561, 1997
37. Dickson J: Hyperthermia in the treatment of cancer. Lancet 1:202-205, 1979
38. Hafström L, Mattsson J: Regional chemotherapy for malignant melanoma. Cancer Treatment Rev 19:17-28, 1993
39. Trieb K, Sztankay A. Amberger A, et al: Hyperthermia inhibits proliferation and stimulates the expression of differentiation markers in thyroid carcinoma cells. Cancer Lett 87:65-71, 1994